PhOx430 / Phost'IN - LARVOL DELTA

First-in-human clinical trial of the acetylglucosaminyltransferase V (GnT-V) inhibitor PhOx430 in patients with advanced solid tumours: the PhAST trial (ESMO 2025) - P1 | "Conclusions PhOx430 was well tolerated at doses up to 1,200 mg qid, had a favorable PK profile, and induced target inhibition, antitumour immune activation and preliminary signs of clinical activity. An expansion phase in patients with selected tumour types is ongoing."

Clinical • First-in-human • Metastases • P1 data • Oncology • Ovarian Cancer • Solid Tumor • CD8

PhAST: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=149 | Recruiting | Sponsor: Phost'In Therapeutics | Trial primary completion date: Jul 2024 ➔ Nov 2024

Metastases • Trial primary completion date • Brain Cancer • Breast Cancer • CNS Tumor • Glioblastoma • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

PhAST: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=149 | Recruiting | Sponsor: Phost'In Therapeutics | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jun 2023 ➔ Jul 2024

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • Breast Cancer • CNS Tumor • Gastrointestinal Cancer • Glioblastoma • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Taiho Pharmaceutical and Phost’in Therapeutics Announce an Option and License Agreement on the First-in-Class GnT-V Inhibitor PhOx430 (Taiho Press Release) - "Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Phost’in Therapeutics...announced that the two companies have entered into an option and license agreement through which Taiho Pharmaceutical will obtain option rights to in-license PhOx430, a First-in-Class small molecule targeting GnT-V (N-acetylglucosaminyltransferase-V). According to the terms of this agreement, Taiho Pharmaceutical will make an upfront payment to Phost’in. In return, Taiho Pharmaceutical will receive an option right to in-license PhOx430 and additional undisclosed compounds and to exclusively develop and commercialize the compounds in Japan and certain other territories in Asia (excluding China)."

Licensing / partnership • Oncology • Solid Tumor

PhAST: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=146 | Recruiting | Sponsor: Phost'In Therapeutics

New P1 trial • Brain Cancer • Breast Cancer • Gastrointestinal Cancer • Glioblastoma • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR